PLAINFIELD – U.S. Sen. Bob Menendez isn’t taking anything for granted.
While he’s running for reelection against a Republican for statewide office in a decidedly-blue state, he acknowledges that the money of Republican front runner Bob Hugin could make the election less than a sure thing.
“Anyone who’s willing to spend 25 or $40 million of their own money, the money that he gets to spend on the backs of cancer patients, can make a dent in an election,” Menendez said. “But, at the end of the day, I’m convinced that my record of success … I think that’s going to be more compelling than his $25 or $40 million.”
Menendez said that Hugin came to Celgene from Wall Street and “drove the company’s profits sucking the blood of cancer patients who had to rely on the one drug that is about 70% of the company.”
“By jacking up the prices over the course of years, by last year alone jacking it up three times, raking in $80 million more than they were already profiting, only to parachute out with $35 million of it,” Menendez told the New Jersey Globe.
Regarding his record, Menendez listed off a series of accomplishments regarding the securing of relief funds for victims of Hurricane Sandy, as well as his role in drafting and passing the Affordable Care Act and his F rating from the National Rifle Association.
The Hugin campaign’s take on Menendez’s record was, unsurprisingly, less stellar than than the senator’s own.
“If Senator Menendez can look New Jerseyans in the eye and honestly tell them their lives are better after his 25 years in Washington, D.C., then he is either clueless or a better liar than we gave him credit for,” Hugin communications director Megan Piwowar said in a statement.
Editor’s note: This article was updated with comment from the Hugin campaign at 4:53 p.m.